Circle Pharma, Inc., a leading biopharmaceutical company specializing in the discovery and development of therapeutically potent macrocycles that can permeate cells, is proud to announce the appointment of Michael Cox, PharmD., MHSc, BCOP as Senior Vice President, Head of Early Development, and Edward Garmey, M.D. as its new Consulting Chief Medical Officer.
With these additions to the leadership team, Circle Pharma is strengthening its efforts in the field of oncology drug development and is aggressively pushing its Cyclin A/B inhibitor program towards clinical trials.
Circle Pharma is delighted to welcome Michael and Edward to the team, whose experience in clinical development and medical affairs will be invaluable in accelerating our mission to develop groundbreaking oncology treatments.
As Circle Pharma enters a period of rapid growth that includes the launch of our Cyclin A/B inhibitor into clinical studies, we look forward to their valuable contribution in bringing transformative macrocycle therapeutics to patients in need. David Earp, our President and CEO, believes their expertise will be key in ensuring successful product advancement.
Dr. Michael Cox is a key contributor to the clinical development mission of the company, providing strategic guidance and supervising early-stage clinical programs. His experience in oncology drug development is extensive, and includes serving as VP of Clinical Development at Day One Biopharmaceuticals, Inc., where he steered global oncology projects through all phases of development, including the development and regulatory strategy for tovorafinib – an investigational pan-RAF kinase inhibitor granted a Breakthrough Therapy designation by the FDA.
Prior to this, he was the executive director of Pediatric Clinical Development & Medical Affairs for Loxo Oncology Inc. (acquired by Eli Lilly and Co.), and contributed to multiple oncology assets, including larotrectinib, selitrectinib and selpercatinib. Dr. Cox’s career also includes roles at Bayer Healthcare AG, Merck KGaA, and Amgen.
Dr. Cox possesses a wealth of knowledge and experience, having earned a Master’s of Health Science in Clinical Research from Duke University, a Doctorate of Pharmacy from Ohio Northern University, as well as completing post-graduate training programs at the National Cancer Institute, the University of Pittsburgh Medical Center, and Mission Hospital in Asheville, North Carolina. This valuable education and experience has helped shape Dr. Cox into the highly skilled and knowledgeable figure that he is today.
Circle Pharma is delighted to welcome Edward Garmey, M.D., as their new Consulting Chief Medical Officer. Dr. Garmey brings with him over 17 years of experience in biopharmaceuticals, including roles as Chief Medical Officer and Senior Vice President at Cerulean Pharma, and Vice President of Clinical Development at ArQule.
He will provide invaluable clinical insight and strategic guidance to the company’s pipeline programs and foster strong partnerships with key stakeholders. His expertise in oncology and hematology and successful background with Cerulean Pharma’s IPO make him a great addition to the Circle Pharma team.
Dr. Garmey is a distinguished alumnus of two Ivy League institutions, Harvard and New York Universities, where he honed the skills necessary for his medical career. His training at Mount Sinai Medical Center, the Children’s Hospital of Los Angeles, and Memorial Sloan-Kettering Cancer Center provided a comprehensive foundation to his practice.
His commitment and dedication to the field of medicine drove him to pursue additional research fellowships at the National Institutes of Health and the Botswana-Harvard Partnership for H.I.V. Research.
About Circle Pharma, Inc.
Circle Pharma, based in South San Francisco, is on a mission to revolutionize the way we treat cancer. Their MXMO™ platform uses innovative structure-based rational drug design and advanced synthetic chemistry to engineer intrinsically cell-permeable macrocycles.
These can be administered through multiple routes, including orally, with the primary focus being on cyclins – master regulators of the cell cycle that are found in many cancers.
With the aim of developing first-in-class treatments for these challenging targets, Circle Pharma is working hard to improve clinical outcomes and to address unmet medical needs.